A super-stable homogeneous Lipiodol-hydrophilic chemodrug formulation for treatment of hepatocellular carcinoma
Authors:
Open Access
- 1 January 2022
- journal article
- research article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 12 (4) , 1769-1782
Abstract
Background: Though lipiodol formulations are major options in transcatheter arterial chemoembolization (TACE) of advanced unresectable hepatocellular carcinoma (HCC) in the clinic, their application is severely limited by insufficient physical stability between the hydrophobic lipiodol and hydrophilic drugs; thus, most chemotherapeutic drugs are quickly released into systemic circulation resulting in poor therapeutic outcomes and serious side effects.Keywords
This publication has 32 references indexed in Scilit:
- Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinomaHepatology, 2015
- Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A reviewCritical Reviews in Oncology/Hematology, 2013
- New Data Supporting Modified RECIST (mRECIST) for Hepatocellular CarcinomaClinical Cancer Research, 2013
- Size Limit for Particle-Stabilized Emulsion Droplets under GravityPhysical Review Letters, 2012
- Nuclear Mapping of Nanodrug Delivery Systems in Dynamic Cellular EnvironmentsACS Nano, 2012
- Ethiodized Oil Uptake Does Not Predict Doxorubicin Drug Delivery after Chemoembolization in VX2 Liver TumorsJournal of Vascular and Interventional Radiology, 2012
- Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletionGut, 2010
- Radioembolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: European Experience on Safety and Long-Term SurvivalHepatology, 2010
- Loco‐regional treatment of hepatocellular carcinoma†Hepatology, 2010
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002